US Edition
News from dermatologytimes.com
We’ve assigned a rating of Unknown factuality to dermatologytimes.com. You can read more about how we’ve determined dermatologytimes.com’s credibility and reliability as a news source here: https://ground.news/rating-system.
Information about dermatologytimes.com
Where is dermatologytimes.com located?dermatologytimes.com's WebsiteMedia Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top dermatologytimes.com News
Amgen · Thousand OaksAmgen Inc. (NASDAQ:AMGN) and Kyowa Kirin released preliminary topline results from the ASCEND study evaluating rocatinlimab in adults and adolescents with moderate to severe atopic dermatitis (AD) on Tuesday. The ongoing ASCEND study, which includes approximately 2,600 patients, is designed to evaluate the long-term safety and efficacy of rocatinlimab (150 mg and 300 mg) administered every four or eight weeks in individuals who completed a previ…See the Story
Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis - Amgen (NASDAQ:AMGN)
84% Center coverage: 13 sources
172 Patients Complete Treatment: Biofrontera's Breakthrough AK Therapy Could Help 58M US Adults
100% Right coverage: 1 sources
